Treating KRAS-G12C and BRAF V600E Genetic Mutations In Metastatic Colorectal Cancer

Not all colorectal cancers are the same. Many tumors contain genetic changes, called mutations, that influence how the cancer grows and which treatments may work best.

For people with metastatic colorectal cancer, biomarker testing has become an essential part of treatment planning. By identifying specific mutations, such as KRAS-G12C or BRAF V600E, doctors can match patients with targeted therapies designed to block the abnormal proteins driving cancer growth.

Several new FDA-approved treatment combinations are changing outcomes for patients with these mutations and offering new options beyond traditional chemotherapy.

Understanding Genetic Mutations in Colorectal Cancer

Genetic mutations are common in colorectal cancer because the disease develops when DNA changes allow cells to grow uncontrollably. Most colorectal cancers contain multiple genetic mutations that accumulate over time.

Sporadic (Acquired) Mutations

Approximately 75–80% of colorectal cancers are sporadic, meaning the mutations develop during a person's lifetime rather than being inherited. Common acquired mutations include:

• APC (70–80%). Often the first mutation involved in colorectal cancer development

• TP53 (40–50%). A tumor suppressor gene that normally helps prevent abnormal cell growth

• KRAS (35–45%). A driver mutation that continuously activates cell growth signals

• PIK3CA (15–20%).

Inherited Mutations

About 5–10% of colorectal cancers are caused by inherited genetic changes passed from parent to child. The most common hereditary syndromes include:

• Lynch syndrome. Caused by inherited mutations in DNA mismatch repair (MMR) genes such as MLH1, MSH2, MSH6, and PMS2.

• Familial Adenomatous Polyposis (FAP). Caused by inherited mutations in the APC gene.

For patients with advanced or metastatic colorectal cancer, biomarker testing is now standard of care because it helps identify mutations that may be treated with targeted therapies.

FDA-Approved Treatments for KRAS-G12C Mutations

Until recently, patients with KRAS-mutated colorectal cancer had few targeted treatment options. Today, two FDA-approved combination therapies specifically target the KRAS-G12C mutation.

Adagrasib (Krazati) + Cetuximab

Approved by the FDA in June 2024, this combination is used for patients with unresectable or metastatic KRAS-G12C-mutated colorectal cancer after prior treatment.

• Adagrasib blocks the abnormal KRAS-G12C protein inside cancer cells.

• Cetuximab blocks EGFR, a protein on the surface of cancer cells that can help tumors continue growing.

By targeting two different pathways at the same time, this combination has shown meaningful responses in patients whose cancer continued to grow after earlier treatments.

Sotorasib (Lumakras) + Panitumumab (Vectibix)

Approved by the FDA in January 2025, this combination is another targeted option for patients with previously treated metastatic KRAS-G12C colorectal cancer.

• Sotorasib blocks the KRAS-G12C mutation.

• Panitumumab blocks EGFR, helping prevent the cancer from bypassing KRAS inhibition.

Together, these medications provide a chemotherapy-free targeted treatment option for patients with this specific mutation.

New First-Line Treatment for BRAF V600E

Approximately 8–12% of patients with metastatic colorectal cancer have a BRAF V600E mutation, which has historically been associated with poorer outcomes.

Results from the BREAKWATER Phase 3 trial (NCT04607421) demonstrated improved response rates and overall survival in patients receiving:

• Encorafenib (Braftovi). Targets the BRAF protein

• Cetuximab (Erbitux). Blocks EGFR

• FOLFIRI chemotherapy

  • Folinic acid (Leucovorin) enhances 5-FU

  • Fluorouracil (5-FU) damages cancer cell DNA

  • Irinotecan prevents cancer cells from repairing DNA damage

Based on these results, the FDA approved encorafenib plus cetuximab with chemotherapy as a first-line treatment option for patients with metastatic colorectal cancer carrying the BRAF V600E mutation.

Because these tumors often respond poorly to chemotherapy alone, combining targeted therapy with chemotherapy offers an important new precision medicine approach.

Why Biomarker Testing Matters

Advances in biomarker testing are helping doctors personalize treatment for metastatic colorectal cancer. Identifying mutations such as KRAS-G12C and BRAF V600E allows patients to receive therapies specifically designed to target the molecular changes driving their cancer.

If you have metastatic colorectal cancer, ask your healthcare team whether comprehensive biomarker testing has been performed and whether targeted therapies may be an option for your treatment plan.

Conclusion

Colorectal cancer is increasing among younger adults, with diagnoses rising by approximately 3% each year in people under age 50. As researchers learn more about the genetic mutations that drive colorectal cancer, treatment continues to become more personalized.

Recent FDA approvals for therapies targeting KRAS-G12C and BRAF V600E represent important advances in precision medicine. For eligible patients, biomarker testing can open the door to treatments that may improve outcomes and provide additional options beyond traditional chemotherapy.